OIS at AAO 2015


Nov 12, 2015 4:40pm ‐ Nov 12, 2015 4:50pm


Alimera Sciences (Nasdaq: ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, manufactures ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg available in the U.S. for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN is also approved in seventeen European countries where it is commercially available in the United Kingdom, Germany and Portugal.


  • Dan Myers, Co-Founder, President & CEO, Alimera

You must be logged in and own this session in order to post comments.